Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

News

Article

September 12, 2023

Therapy to Prevent PSA-Related Recurrence May Not Boost Prostate Cancer Survival

Author(s):

Brielle Benyon

Treatments intended to reduce biochemical recurrence in patients with prostate cancer may not improve long-term survival, recent research showed.

prostate-specific antigen (PSA) test | Image credit: © luchschenF - © stock.adobe.com

Rising prostate-specific antigen (PSA) levels indicate biochemical recurrence of prostate cancer.

Certain prostate cancer treatments used to reduce the risk of post-radiotherapy biochemical recurrence may not improve long-term overall survival, according to research published in the Journal of Clinical Oncology.

“Prostate cancer is fairly unique among cancers in that we have a good lab test (PSA) that tells us if there is cancer present or not,” study author Dr. Amar U. Kishan, an associate professor of radiation oncology at the David Geffen School of Medicine at UCLA and a researcher at the UCLA Health Jonsson Comprehensive Cancer Center, said in an interview with CURE®.

Biochemical recurrence, according to the National Institutes of Health, is the state of rising prostate-specific antigen (PSA) levels in patients who have been treated for prostate cancer.

“Specifically, a rising PSA after treatment above a certain threshold signifies that there is a recurrence. Because this is based off a lab test, rather than a scan result or a clinical symptom, this is called a ‘biochemical’ recurrence. Generally, this is diagnosed much earlier than a normal recurrence. This is part of the reason why prostate cancer survival is high even if it recurs — biochemical recurrences are caught very early, before the cancer has progressed enough to be visible on a scan or cause symptoms,” Kishan said.

Kishan and his team evaluated patient data from 11 randomized trial to determine if treatments that are administered with the goal of reducing biochemical recurrence after radiation have an outcome on overall survival, which is the time patients live before dying of any cause.

Notably, the post-radiotherapy treatments studied were dose escalation, androgen deprivation therapy (ADT), ADT prolongation and radiotherapy dose escalation. These therapies significantly improved the risk of biochemical recurrence, though when the researchers accounted for biochemical recurrence and non-cancer-related deaths, there was no association observed between the therapies and improved survival.

“What we show is that treatment intensification strategies that reduce the initial recurrence after radiation (the biochemical recurrence, based on PSA) do not necessarily prolong life. This has implications mostly for clinical trial design and for practitioners on what the bar should be to incorporate new treatments into practice,” Kishan said.

Kishan explained that it usually takes a long time for researchers to “read out” long-term studies on prostate cancer because people tend to live a long time with the disease and treatment intensification strategies are often adopted early, he said.

“We should be mindful of the current study's results when designing clinical trials and also when appraising evidence to support intensification strategies in the absence of evidence of survival or true surrogate endpoints being improved,” Kishan said. Of note, a surrogate marker or endpoint is a specific early outcome that should be able to reliably predict a long-term clinical outcome, such as disease recurrence or death.

While the research team analyzed overall survival, the study did not consider quality of life, which Kishan mentioned is extremely important for patients with prostate cancer.

“We only looked at whether biochemical recurrence was a surrogate for overall survival. While that ended up not being the case, I think we can see a clear gap in our understanding of the other half of the survivorship journey: quality of life,” he said. “It may very well be true that reducing recurrence improves quality of life, even it doesn't improve overall survival. Unfortunately, most trials have not been designed to detect that and therefore we can't conclude that. Ultimately, each patient must discuss with their doctor what their priorities and their family's priorities are when embarking on a course of treatment.”


For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of Doctor.
Image of Dr. Tagawa.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.
Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, at the Norton Healthcare Institute, in Louisville, Kentucky.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Image of man with black hair.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Related Content
Advertisement
The addition of Erleada to ADT may provide less benefit in patients with metastatic castration-sensitive prostate cancer and fewer bone metastases: © stock.adobe.com.
May 14th 2025

Bone Metastasis Count May Guide Erleada Treatment in Prostate Cancer

Spencer Feldman
The addition of Erleada to ADT may provide less benefit in patients with metastatic castration-sensitive prostate cancer and fewer bone metastases.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
The first patient has been enrolled in the ARID II trial for prostate cancer: stock.adobe.com.
April 24th 2025

First Patient Enrolled in ARID II Trial for Prostate Cancer Treatment

Spencer Feldman
The first patient has been enrolled in the ARID II trial evaluating Voro Urologic Scaffold to improve continence after prostate cancer surgery.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Image of man.
April 15th 2025

Nubeqa Combo Improves Outcomes in Metastatic Prostate Cancer

Kristi Rosa
Nubeqa plus hormone therapy improved outcomes in metastatic prostate cancer, reducing disease progression and showing a favorable safety profile.
Image of man and doctor.
April 12th 2025

NeuroSAFE May Increase Erectile Function After Prostate Cancer Surgery

Alex Biese
Use of NeuroSAFE during prostatectomy nearly doubled the number of patients who had no or mild erectile dysfunction approximately a year later.
Related Content
Advertisement
The addition of Erleada to ADT may provide less benefit in patients with metastatic castration-sensitive prostate cancer and fewer bone metastases: © stock.adobe.com.
May 14th 2025

Bone Metastasis Count May Guide Erleada Treatment in Prostate Cancer

Spencer Feldman
The addition of Erleada to ADT may provide less benefit in patients with metastatic castration-sensitive prostate cancer and fewer bone metastases.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
The first patient has been enrolled in the ARID II trial for prostate cancer: stock.adobe.com.
April 24th 2025

First Patient Enrolled in ARID II Trial for Prostate Cancer Treatment

Spencer Feldman
The first patient has been enrolled in the ARID II trial evaluating Voro Urologic Scaffold to improve continence after prostate cancer surgery.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Image of man.
April 15th 2025

Nubeqa Combo Improves Outcomes in Metastatic Prostate Cancer

Kristi Rosa
Nubeqa plus hormone therapy improved outcomes in metastatic prostate cancer, reducing disease progression and showing a favorable safety profile.
Image of man and doctor.
April 12th 2025

NeuroSAFE May Increase Erectile Function After Prostate Cancer Surgery

Alex Biese
Use of NeuroSAFE during prostatectomy nearly doubled the number of patients who had no or mild erectile dysfunction approximately a year later.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.